LYLi Yan

Li Yan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Li Yan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antifungal use with and without fungal diagnoses among patients with septic shock in a retrospective multicenter cohort

    by Robert J. Flick, Li Yan, Nicholas A. Bosch, Anica C. Law, Khyzer B. Aziz, Chad H. Hochberg, Joseph Levy, Theodore J. Iwashyna

    INTRODUCTION Sepsis caused by fungal organisms is associated with higher mortality and longer time to diagnosis.(,) Estimates of the incidence of fungal infections among patients with sepsis in the United States have not been reported since 2000 and did not specifically address those with septic shock.() There have since been changes in sepsis management and […] INTRODUCTION Sepsis caused by fungal organisms is associated with higher mortality and longer time to diagnosis.(,) Estimates of the incidence of fungal infections among patients with sepsis in the United States have not been reported since 2000 and did not specifically address those with septic shock.() There have since been changes in sepsis management and […]

  • Open Access

    Antifungal use with and without fungal diagnoses in septic shock across U.S. hospitals, 2022-2024

    by Robert J Flick, Li Yan, Anica C Law, Chad H Hochberg, Joseph Levy, Theodore J. Iwashyna, Nicholas A Bosch

    Septic shock caused by fungal organisms is characterized by high mortality and diagnostic complexity. We used the Premier Healthcare Database to characterize antifungal use and fungal diagnoses among adults with septic shock requiring vasopressors admitted between October 2022 through July 2024. Among 12.8 million admission at 886 hospitals, 554,948 met septic shock criteria and were included for analysis. A fungal diagnosis was established in 11,405 (2.1%) of encounters; of these, 3,565 (31.3%) received intravenous antifungal therapy within one day of vasopressor initiation. In the overall cohort, antifungal therapy was initiated in 29,824 (5.5%) within one day of vasopressor initiation; of these, 3,656 (12.2%) were ultimately diagnosed with a fungal infection. In the 116 hospitals reporting microbiological data, a subgroup of 489 encounters with septic shock and culture-confirmed candidemia was identified. In this subgroup, intravenous antifungal therapy was initiated in 43.8% within one day, 63.8% within three days, and 78.9% within seven days. These findings highlight a profound decoupling between fungal diagnosis and treatment—few patients receiving antifungals were diagnosed with an infection that would be treated by these agents, while less than half of patients with septic shock and candidemia received timely treatment. Strategies for greater precision in empiric antifungal use in septic shock are needed to improve safety, stewardship, and outcomes.

  • Open Access

    Patterns and outcomes of real-world high-flow nasal cannula use: a multi-hospital retrospective cohort study

    by Diana C. Bouhassira, Chad H. Hochberg, Sarina K. Sahetya, Ann Parker, Khyzer B. Aziz, Li Yan, Theodore John Iwashyna

    Objective: To characterize real-world high-flow nasal cannula use and outcomes. Methods: A retrospective observational study using an electronic health record registry of all adult patients in a five-hospital system between 2017 – 2025. We identified all high-flow nasal cannula episodes, defined as periods of high-flow nasal cannula use containing breaks no longer than 6 […] ABSTRACT Objective: To characterize real-world high-flow nasal cannula use and outcomes. Methods: A retrospective observational study using an electronic health record registry of all adult patients in a five-hospital system between 2017 – 2025. We identified all high-flow nasal cannula episodes, defined as periods of high-flow nasal cannula use containing breaks no longer than 6 […]